Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 3;2(2):CD009081.
doi: 10.1002/14651858.CD009081.pub2.

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia

Carole Parsons  1 , Wei Yin Lim  2 , Clement Loy  3 , Bernadette McGuinness  4 , Peter Passmore  4 , Stephanie A Ward  5 , Carmel Hughes  1
Affiliations

Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia

Carole Parsons et al. Cochrane Database Syst Rev. .

Abstract

Background: Dementia is a progressive syndrome characterised by deterioration in memory, thinking and behaviour, and by impaired ability to perform daily activities. Two classes of drug - cholinesterase inhibitors (donepezil, galantamine and rivastigmine) and memantine - are widely licensed for dementia due to Alzheimer's disease, and rivastigmine is also licensed for Parkinson's disease dementia. These drugs are prescribed to alleviate symptoms and delay disease progression in these and sometimes in other forms of dementia. There are uncertainties about the benefits and adverse effects of these drugs in the long term and in severe dementia, about effects of withdrawal, and about the most appropriate time to discontinue treatment.

Objectives: To evaluate the effects of withdrawal or continuation of cholinesterase inhibitors or memantine, or both, in people with dementia on: cognitive, neuropsychiatric and functional outcomes, rates of institutionalisation, adverse events, dropout from trials, mortality, quality of life and carer-related outcomes.

Search methods: We searched the Cochrane Dementia and Cognitive Improvement Group's Specialised Register up to 17 October 2020 using terms appropriate for the retrieval of studies of cholinesterase inhibitors or memantine. The Specialised Register contains records of clinical trials identified from monthly searches of a number of major healthcare databases, numerous trial registries and grey literature sources.

Selection criteria: We included all randomised, controlled clinical trials (RCTs) which compared withdrawal of cholinesterase inhibitors or memantine, or both, with continuation of the same drug or drugs.

Data collection and analysis: Two review authors independently assessed citations and full-text articles for inclusion, extracted data from included trials and assessed risk of bias using the Cochrane risk of bias tool. Where trials were sufficiently similar, we pooled data for outcomes in the short term (up to 2 months after randomisation), medium term (3-11 months) and long term (12 months or more). We assessed the overall certainty of the evidence for each outcome using GRADE methods.

Main results: We included six trials investigating cholinesterase inhibitor withdrawal, and one trial investigating withdrawal of either donepezil or memantine. No trials assessed withdrawal of memantine only. Drugs were withdrawn abruptly in five trials and stepwise in two trials. All participants had dementia due to Alzheimer's disease, with severities ranging from mild to very severe, and were taking cholinesterase inhibitors without known adverse effects at baseline. The included trials randomised 759 participants to treatment groups relevant to this review. Study duration ranged from 6 weeks to 12 months. There were too few included studies to allow planned subgroup analyses. We considered some studies to be at unclear or high risk of selection, performance, detection, attrition or reporting bias. Compared to continuing cholinesterase inhibitors, discontinuing treatment may be associated with worse cognitive function in the short term (standardised mean difference (SMD) -0.42, 95% confidence interval (CI) -0.64 to -0.21; 4 studies; low certainty), but the effect in the medium term is very uncertain (SMD -0.40, 95% CI -0.87 to 0.07; 3 studies; very low certainty). In a sensitivity analysis omitting data from a study which only included participants who had shown a relatively poor prior response to donepezil, inconsistency was reduced and we found that cognitive function may be worse in the discontinuation group in the medium term (SMD -0.62; 95% CI -0.94 to -0.31). Data from one longer-term study suggest that discontinuing a cholinesterase inhibitor is probably associated with worse cognitive function at 12 months (mean difference (MD) -2.09 Standardised Mini-Mental State Examination (SMMSE) points, 95% CI -3.43 to -0.75; moderate certainty). Discontinuation may make little or no difference to functional status in the short term (SMD -0.25, 95% CI -0.54 to 0.04; 2 studies; low certainty), and its effect in the medium term is uncertain (SMD -0.38, 95% CI -0.74 to -0.01; 2 studies; very low certainty). After 12 months, discontinuing a cholinesterase inhibitor probably results in greater functional impairment than continuing treatment (MD -3.38 Bristol Activities of Daily Living Scale (BADLS) points, 95% CI -6.67 to -0.10; one study; moderate certainty). Discontinuation may be associated with a worsening of neuropsychiatric symptoms over the short term and medium term, although we cannot exclude a minimal effect (SMD - 0.48, 95% CI -0.82 to -0.13; 2 studies; low certainty; and SMD -0.27, 95% CI -0.47 to -0.08; 3 studies; low certainty, respectively). Data from one study suggest that discontinuing a cholinesterase inhibitor may result in little to no change in neuropsychiatric status at 12 months (MD -0.87 Neuropsychiatric Inventory (NPI) points; 95% CI -8.42 to 6.68; moderate certainty). We found no clear evidence of an effect of discontinuation on dropout due to lack of medication efficacy or deterioration in overall medical condition (odds ratio (OR) 1.53, 95% CI 0.84 to 2.76; 4 studies; low certainty), on number of adverse events (OR 0.85, 95% CI 0.57 to 1.27; 4 studies; low certainty) or serious adverse events (OR 0.80, 95% CI 0.46 to 1.39; 4 studies; low certainty), and on mortality (OR 0.75, 95% CI 0.36 to 1.55; 5 studies; low certainty). Institutionalisation was reported in one trial, but it was not possible to extract data for the groups relevant to this review.

Authors' conclusions: This review suggests that discontinuing cholinesterase inhibitors may result in worse cognitive, neuropsychiatric and functional status than continuing treatment, although this is supported by limited evidence, almost all of low or very low certainty. As all participants had dementia due to Alzheimer's disease, our findings are not transferable to other dementia types. We were unable to determine whether the effects of discontinuing cholinesterase inhibitors differed with baseline dementia severity. There is currently no evidence to guide decisions about discontinuing memantine. There is a need for further well-designed RCTs, across a range of dementia severities and settings. We are aware of two ongoing registered trials. In making decisions about discontinuing these drugs, clinicians should exercise caution, considering the evidence from existing trials along with other factors important to patients and their carers.

PubMed Disclaimer

Conflict of interest statement

CP, CH, BMcG, WYL, SAW have no known conflicts of interest.

PP was an investigator in a donepezil‐licensing European study. He has received honoraria and educational and clinical trial grants from manufacturers of acetylcholinesterase inhibitors and memantine.

CL has received a Wellcome Trust Travelling Award in relation to his work with Cochrane.

Figures

1
1
Study flow diagram.
2
2
Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
3
3
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
1.1
1.1. Analysis
Comparison 1: Cognitive function, Outcome 1: Cognitive function (change from baseline, short term)
1.2
1.2. Analysis
Comparison 1: Cognitive function, Outcome 2: Cognitive function (change from baseline, medium term)
1.3
1.3. Analysis
Comparison 1: Cognitive function, Outcome 3: Cognitive function (change in SMMSE from baseline, long term)
1.4
1.4. Analysis
Comparison 1: Cognitive function, Outcome 4: Cognitive function (change in BPMSE from baseline, medium term) for Hong 2018
1.5
1.5. Analysis
Comparison 1: Cognitive function, Outcome 5: Cognitive function (change in MMSE from baseline, medium term) for Hong 2018
2.1
2.1. Analysis
Comparison 2: Functional status, Outcome 1: Functional status (change from baseline, short term)
2.2
2.2. Analysis
Comparison 2: Functional status, Outcome 2: Functional status (change from baseline, medium term)
2.3
2.3. Analysis
Comparison 2: Functional status, Outcome 3: Functional status (change from baseline, long term)
3.1
3.1. Analysis
Comparison 3: Neuropsychiatric status, Outcome 1: Neuropsychiatric status (change from baseline, short term)
3.2
3.2. Analysis
Comparison 3: Neuropsychiatric status, Outcome 2: Neuropsychiatric status (change from baseline, medium term)
3.3
3.3. Analysis
Comparison 3: Neuropsychiatric status, Outcome 3: Neuropsychiatric status (change in NPI from baseline, long term)
4.1
4.1. Analysis
Comparison 4: Quality of life, Outcome 1: Quality of life (change in QUALID from baseline, short term)
5.1
5.1. Analysis
Comparison 5: Safety, tolerability and dropout, Outcome 1: Total dropout during trial and follow‐up
5.2
5.2. Analysis
Comparison 5: Safety, tolerability and dropout, Outcome 2: Dropout due to adverse event
5.3
5.3. Analysis
Comparison 5: Safety, tolerability and dropout, Outcome 3: Dropout due to lack of efficacy of trial medication or deterioration in overall medical condition
5.4
5.4. Analysis
Comparison 5: Safety, tolerability and dropout, Outcome 4: Adverse events (any)
5.5
5.5. Analysis
Comparison 5: Safety, tolerability and dropout, Outcome 5: Serious adverse events (SAEs)
5.6
5.6. Analysis
Comparison 5: Safety, tolerability and dropout, Outcome 6: Deaths
See this image and copyright information in PMC

Update of

References

References to studies included in this review

DOMINO AD Howard {published and unpublished data}
    1. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and memantine for moderate-to-severe Alzheimer's disease. The New England Journal of Medicine 2012;366:893-903. - PubMed
    1. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Nursing home placement in the donepezil and memantine in moderate to severe Alzheimer's disease (DOMINO-AD) trial: secondary and post-hoc analyses. The Lancet Neurology 2015;14(12):1171-81. - PubMed
    1. Jones R, Sheehan B, Phillips P, Juszczak E, Adams J, Baldwin A, et al. DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT. Trials 2009;10:57. - PMC - PubMed
    1. Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, et al. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's Disease (the DOMINO-AD trial). International Journal of Geriatric Psychiatry 2017;32:1205-16. - PMC - PubMed
    1. McShane R [pers comm]. Email to: C Parsons 2 December 2015.
GAL‐ITA‐2 Scarpini {published data only}
    1. Janssen Research and Development. Clinical Study Report Synopsis GAL ITA 2; Phase III JNJ-17335630-AAD (Galantamine). The Yale University Open Data Access (YODA) Project. Accessed November 2015.
    1. Scarpini E, Bruno G, Zappalà G, Adami M, Richarz U, Gaudig M, et al. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's Disease: a randomized, double blind, placebo controlled withdrawal trial. Journal of Alzheimer's Disease 2011;26:211-20. - PubMed
GAL‐USA‐5 Gaudig {published and unpublished data}
    1. Gaudig M, Richarz U, Van Baelen B, Schauble B. Effects of galantamine in Alzheimer's disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment. Current Alzheimer Research 2011;8:771-80. - PubMed
    1. Janssen Research Foundation. Safety and efficacy of galantamine during its withdrawal in the treatment of Alzheimer's Disease. Clinical Research Report February 12, 1999.
Herrmann 2016 {published data only}
    1. Hermann N, O'Regan J, Ruthirakuhan M, Kiss A, Eryavec G, Williams E, et al. A randomized placebo-controlled discontinuation study of cholinesterase inhibitors in institutionalized patients with moderate to severe Alzheimer disease. Journal of the American Medical Directors Association 2016;17(2):142-7. - PubMed
Holmes 2004 {published data only}
    1. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-19. - PubMed
Hong 2018 {published data only (unpublished sought but not used)}
    1. Hong YJ, Choi SH, Jeong JH, Park KW, Na HR. Effectiveness of anti-dementia drugs in extremely severe Alzheimer's disease: a 12-week, multicenter, randomized, single-blind study. Journal of Alsheimer's Disease 2018;63:1035-44. - PubMed
Johannsen 2006 {published data only}
    1. Johannsen P, Salmon E, Hampel H, Xu Y, Richardson S, Qvitzau S, et al. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's Disease. CNS Drugs 2006;20(4):311-25. - PubMed
    1. Kozubski W, Hasselbach C, Jakab G, Kalisvaart CJ, Kurz A, McCarthy J, et al. Donepezil-treated Alzheimer's disease patients with apparent initial cognitive decline demonstrate significant benefits when therapy is continued: results from a randomised, placebo-controlled trial. European Neuropsychopharmacology 2003;13(4):S405.

References to studies excluded from this review

Adami 2011 {published data only}
    1. Adami M, Scarpini E, Bruno G, Zappala G, Richarz U, Gaudig M, et al. Cessation versus continuation of 12 months galantamine therapy in patients with Alzheimer's disease: a randomised, double blind, placebo controlled withdrawal trial. Alzheimer's and Dementia 2011;7(4S Part 23):S794. - PubMed
Antonanzas 2006 {published data only}
    1. Antonanzas F, Rive B, Badenas JM, Gomez-Lus S, Guilhaume C. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: an adaptation in Spain. European Journal of Health Economics 2006;7:137-44. - PubMed
Bogardus 2001 {published data only}
    1. Bogardus ST. When should one stop cholinesterase inhibitors in patients with Alzheimer's disease? Journal of Psychiatry and Neuroscience 2001;26(5):425. - PMC - PubMed
Daiello 2009 {published data only}
    1. Daiello LA, Ott BR, Lapane KL, Reinert SE, Machan JT, Dore DD. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. The American Journal of Geriatric Pharmacotherapy 2009;7:74-83. - PubMed
Doody 2004 {published data only}
    1. Doody R, Pratt RD, Posner H, Kumar D. Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits. Neurobiology of Aging 2004;25(2):S469-70.
Farlow 2003 {published data only}
    1. Farlow M, Potkin S, Koumaras B, Veach J, Mirski D. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial. Archives of Neurology 2003;60:843-8. - PubMed
Feldman 2003 {published data only}
    1. Feldman H, Gauthier S, Vellas B, Hecker J, Xu Y, Jeni J, et al. Donepezil has significant benefits on behavior in patients with severe Alzheimer's Disease. American Psychiatric Association 2003 Annual Meeting Research Abstracts 2003;1:330.
Ferris 2001 {published data only}
    1. Ferris SH. Switching previous therapies for Alzheimer's Disease to galantamine. Clinical Therapeutics 2001;23(Suppl A):A3-7. - PubMed
Frankfort 2006 {published data only}
    1. Frankfort SV, Appels BA, De Boer A, Tulner LR, Van Campen JP, Kwoks CH, et al. Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting. International Journal of Clinical Practice 2006;60(6):646-54. - PubMed
GAL‐USA‐11 Gaudig {published data only}
    1. Gaudig M, Richarz U, Han J, Van Baelen B, Schauble B. Effects of galantamine in Alzheimer's Disease: double-blind withdrawal studies evaluating sustained versus interrupted treatment. Current Alzheimer Reserach 2011;8:771-80. - PubMed
Gaudig 2011 {published data only}
    1. Gaudig M, Richarz U, Rettig K, Djelani M, Schauble B. Effectiveness of galantamine in patients with mild-to-moderate dementia: 12 months' outcome data. Alzheimer's & Dementia 2012;8(4):S592.
Grossberg 2003 {published data only}
    1. Grossberg GT. Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and staying on. Current Therapeutic Research 2003;64(4):216-7. - PMC - PubMed
Howard 2011 {published data only}
    1. Howard R, Phillips P, Johnson T, O'Brien J, Lindesay J, Bentham P, et al. Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry 2011;26:812-7. - PubMed
Howard 2012 {published data only}
    1. Howard R, Phillips P, Gray R. Discontinuing donepezil or starting memantine for Alzheimer's disease. The New England Journal of Medicine 2012;366(23):2227-8. - PubMed
Kwak 2009 {published data only}
    1. Kwak YT, Han IW, Suk SH, Koo MS. Two cases of discontinuation syndrome following cessation of memantine. Geriatrics & Gerontology International 2009;9:203-5. - PubMed
Le Couteur 2012 {published data only}
    1. Le Couteur DG, Robinson M, Leverton A, Creasey H, Waite L, Atkins A, et al. Adherence, persistence and continuation with cholinesterase inhibitors in Alzheimer's disease. Australasian Journal on Ageing 2012;31(3):164-9. - PubMed
Maclure 2009 {published data only}
    1. Maclure M, Green CJ, Jacova C, Hsiung RG. Pragmatic randomized trial of continuing cholinesterase inhibitors among indeterminate responders. Pharmacoepidemiology and Drug Safety 2009;18:S45-6.
Mansour 2011 {published data only}
    1. Mansour D, Wong R, Kuskowski M, Dysken M. Discontinuation of acetylcholinesterase inhibitor treatment in the nursing home. The American Journal of Geriatric Pharmacotherapy 2011;9(5):345-50. - PubMed
Moo 2019 {published data only (unpublished sought but not used)}
    1. Moo L, Martinez E, Dunay M, Thielke S. Cholinesterase inhibitor taper worsens symptoms in patients with Parkinson's disease. Neurology 2019;92(15 Supplement):P2.8-046.
Morris 2001a {published data only}
    1. Morris JC. Overview. Clinical Therapeutics 2001;23(Suppl A):A1-2. - PubMed
Morris 2001b {published data only}
    1. Morris JC, Farlow MR, Ferris SH, Kurz AF, Maelicke A, Rasmusen L, et al. Panel discussion: recommendations for prescribers. Clinical Therapeutics 2001;23(Suppl A):A31-A39. - PubMed
Pariente 2008 {published data only}
    1. Pariente A, Helmer C, Merliere Y, Moore N, Fourrier-Reglat A, Dartigues JF. Prevalence of cholinesterase inhibitors in subjects with dementia in Europe. Pharmacoepidemiology and Drug Safety 2008;17:655-60. - PubMed
Perhach 2011 {published data only}
    1. Perhach J, Graham S. A long-term, open-label extension study evaluating the safety of extended-release memantine (28 mg) in patients with moderate to severe Alzheimer's disease. Alzheimer's & Dementia 2011;7(4):Se70.
Peyro Saint‐Paul 2015 {published data only}
    1. Peyro Saint-Paul L, Martin J, Gaillard C, Garnier A, Mosquet B, Guillamo JS, et al. Sudden discontinuation of anti-dementia drugs in moderate and severe Alzheimer's disease in a residency for dependent elderly people: a longitudinal descriptive pilot study. Therapie 2015;70(4):313-9. - PubMed
Raskind 2004 {published data only}
    1. Raskind MA, Peskind ER, Trueyn L, Kershaw P, Damaraju CR. The cognitive benefits of galantamine are sustained for at least 36 months. Archives of Neurology 2004;61:252-6. - PubMed
Richarz 2011 {published data only}
    1. Richarz U, Gaudig M, Adami M, Jacobs A, Schreiner A. Predictors of outcome in patients with mild to moderate Alzheimer's disease treated with galantamine. European Journal of Neurology 2011;18(S2):354.
Rockwood 2001 {published data only}
    1. Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. Journal of Neurology, Neurosurgery and Psychiatry 2001;71:589-95. - PMC - PubMed
Rockwood 2008 {published data only}
    1. Rockwood K, Dai D, Mitnitski A. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months. International Journal of Geriatic Psychiatry 2008;23:207-14. - PubMed
Schaeuble 2011a {published data only}
    1. Schauble B, Kavanagh S, Van Baelan B. Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study. Alzheimer's & Dementia 2011;7(4):S788. - PubMed
Schaeuble 2011b {published data only}
    1. Schauble B, Gaudig M, Richarz U, Kavanagh S, Van Baelan B. Predictors to long-term treatment response to galantamine. Alzheimer's & Dementia 2011;7(4):S665.
Schneider 2012 {published data only}
    1. Schneider LS. Could cholinesterase inhibitors be harmful over the long term? International Psychogeriatrics 2012;24(2):171-4. - PubMed
Schwalen 2004 {published data only}
    1. Schwalen S, Blesa R, Van Baelen B, Kavanagh S, Janssen-Cilag GmBH. Effects of continuous, interrupted and delayed galantamine treatment on long-term cognitive function in patients with advanced-moderate Alzheimer's disease. The Journal of Nutrition, Health and Aging 2004;8(4):262.
Singh 2003 {published data only}
    1. Singh S, Dudley C. Discontinuation syndrome following donepezil cessation. International Journal of Geriatric Psychiatry 2003;18:282-4. - PubMed
Umegaki 2008 {published data only}
    1. Umegaki H, Itoh A, Suzuki Y, Nabeshima T. Discontinuation of donepezil for the treatment of Alzheimer's disease in geriatric practice. International Psychogeriatrics 2008;20(4):800-6. - PubMed
Waldemar 2008 {published data only}
    1. Waldemar G, Hyvarinen M, Josiassen MK, Korner A, Lehto H, Wetterberg P. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease. International Journal of Geriatric Psychiatry 2008;23:979-81. - PubMed

References to ongoing studies

ISRCTN12134230 {published data only}
    1. Soler A, Amer G, Leiva A, Ripoli J, Llorente MA, Leiva A, et al. Continuation versus discontinuation of treatment for severe dementia: randomized, pragmatic, open-label, clinical trial to evaluate efficacy of continuing drug treatment in patients with severe dementia (STOP-DEM). BMC Geriatrics 2019;19(101):1-9. - PMC - PubMed
NCT02248636 {published data only}
    1. Cholinesterase inhibitor discontinuation (CID). Ongoing study. January 2015. Contact author for more information.

Additional references

Alexopoulos 1988
    1. Alexopoulos G, Abrams R, Young R, Shamoian C. Cornell Scale for Depression in Dementia. Biological Psychiatry 1988;23:271-84. - PubMed
Alzheimer's Disease International 2009
    1. Alzheimer's Disease International. World Alzheimer Report. London, UK: Alzheimer's Disease International; 2009.
Alzheimer's Disease International 2016
    1. Alzheimer's Disease International. World Alzheimer Report. London (UK): Alzheimer's Disease International; 2016.
American Psychiatric Association 1994
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th edition. Washington DC, USA: American Psychiatric Association, 1994.
Amici 2001
    1. Amici S, Lanari A, Romani R, Antognelli C, Gallai V, Parnetti L. Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmine. Mechanisms of Ageing and Development 2001;122:2057-62. - PubMed
Atri 2012
    1. Atri A, Rountree SD, Lopez OL, Doody RS. Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease. Neurodegenerative Diseases 2012;10(1-4):170-4. - PMC - PubMed
Beecham 2001
    1. Beecham J, Knapp M. Costing psychiatric interventions. In: Thornicroft G, editors(s). Measuring mental health needs. London: Gaskell, 2001:200-24.
Black 2007
    1. Black SE, Doody RS, Li H. Donepezil preserves cognition and global function in severe Alzheimer's disease patients. Neurology 2007;69:459-469. - PubMed
Bucks 1996
    1. Bucks RS, Ashworth DL, Wilcock GK, Siegfried K. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age and Ageing 1996;25:113-20. - PubMed
Bullock 2005
    1. Bullock R, Dengiz A. Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. International Journal of Clinical Practice 2005;59(7):817-22. - PubMed
Burns 2007
    1. Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease. International Journal of Geriatric Psychiatry 2007;22:806-12. - PubMed
Burns 2009
    1. Burns A, Iliffe S. Dementia. British Medical Journal 2009;338:405-9.
Cohen‐Mansfield 1988
    1. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. Journal of Gerontology 1988;44(3):M77-84. - PubMed
Courtney 2004
    1. Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double blind trial. Lancet 2004;363:2105-15. - PubMed
Cummings 1994
    1. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44(12):2308-14. - PubMed
Darreh‐Shori 2006
    1. Darreh-Shori T, Meurling L, Petersson T, Hugosson K, Hellstrom-Lindahl E, Anreasen N, et al. Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment. Journal of Neural Transmission 2006;113:1791-801. - PubMed
Darreh‐Shori 2010
    1. Darreh-Shori T, Sioninen H. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies. Current Alzheimer Research 2010;7:67-73. - PubMed
Davidsson 2001
    1. Davidsson P, Blennow K, Andreasen N, Eriksson B, Minthon L, Hesse C. Differential increase in cerebrospinal fluid-acetylcholinesterase after treatment with acetylcholinesterase inhibitors in patients with Alzheimer's disease. Neuroscience Letters 2001;300:157-60. - PubMed
Deardorff 2015
    1. Deardorff WJ, Feen E, Grossberg GT. The use of cholinesterase inhibitors across all stages of Alzheimer's disease. Drugs and Aging 2015;32:537-47. - PubMed
Doody 1999
    1. Doody RS, Strehlow SL, Massman PJ, Feher EP, Clark C, Roy JR. Baylor profound mental status examination: a brief staging measure for profoundly demented Alzheimer disease patients. Alzheimer Disease and Associated Disorders 1999;13(1):53-9. - PubMed
Doody 2001
    1. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD, for the Donepezil Study Group. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer Disease. Archives of Neurology 2001;58:427-33. - PubMed
Farlow 2005
    1. Farlow MR, Lilly ML, ENA713 B352 Study Group. Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years. BMC Geriatrics 2005;5(3):1-7. - PMC - PubMed
Farlow 2013
    1. Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Somogyi M. A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's Dementia. CNS Neuroscience & Therapeutics 2013;19:745-52. - PMC - PubMed
Farlow 2015
    1. Farlow MR, Grossberg GT, Sadowsky CH, Meng X, Velting DM. A 24-week open-label extension study to investigate the long-term safety, tolerability and efficacy of 13.3mg/24h rivastigmine patch in patients with severe Alzheimer disease. Alzheimer Disease and Associated Disorders 2015;29(2):110-16. - PubMed
Feldman 2001
    1. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57(4):613-20. - PubMed
Feldman 2009
    1. Feldman HH, Pirttila T, Dartigues JF, Everitt B, Van Baelen B, Schwalen S, et al. Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease. International Journal of Geriatric Psychiatry 2009;24:479-88. - PubMed
Folstein 1975
    1. Folstein M, Folstein S, McHugh P. Mini-mental state: a practical method for grading the cognitive status of patients for the clinician. Journal of Psychiatric Research 1975;12:189-98. - PubMed
Förstl 2011
    1. Förstl H, Stamouli SS, Janetzky W, Galanopoulos A, Karageorgiou C, Tzanakaki M. Memantine in everyday clinical practice: a comparison of studies in Germany and Greece. Dementia and Geriatric Cognitive Disorders 2011;32(4):267-72. - PubMed
Fox 2012
    1. Fox C, Crugel M, Maidment I, Auestad BH, Coulton S, Treloar A, et al. Efficacy of memantine for agitation in Alzheimer's dementia: a randomised double-blind placebo controlled trial. PLoS ONE 2012;7(5):Article ID e35185. - PMC - PubMed
Galasko 2005
    1. Galasko DR, Schmitt FA, Thomas R, Jin S, Bennett D, Ferris S. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. Journal of the International Neuropsychological Society 2005;11:446-53. - PubMed
Geldmacher 2003a
    1. Geldmacher DS, Provenanzo G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer's disease. Journal of the American Geriatrics Society 2003;51:937-44. - PubMed
Gelinas 1999
    1. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment for Dementia. The American Journal of Occupational Therapy 1999;53:471-81. - PubMed
Gill 2009
    1. Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand ST, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Archives of Internal Medicine 2009;169:867-73. - PubMed
Goldberg 1997
    1. Goldberg DP, Gater R, Sartorius N, Ustun TB, Piccinelli M, Gureje O, et al. The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychological Medicine 1997;27:191-7. - PubMed
Grossberg 2013
    1. Grossberg GT, Manes F, Allegri RF, Gutierrez-Robledo LM, Gloger S, Xie L, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs 2013;27:469-78. - PMC - PubMed
Guy 1976
    1. Guy W. CGI: Clinical Global Impressions. In: ECDEU Assessment manual for psychopharmacology. Rockville, MD: US Department of Health, Education and Welfare, ADAMHA, MIMH Psyhcopharmacology Research Branch, 1976:218-22.
Guyatt 2008
    1. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008;336:924. - PMC - PubMed
Hardy 2002
    1. Hardy J, Selkoe SJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297(5580):353-6. - PubMed
Hernandez 2009
    1. Hernandez RK, Farwell W, Cantor MD, Lawler EV. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system. Journal of the American Geriatrics Society 2009;57(11):1997-2003. - PubMed
Herrmann 2007a
    1. Herrmann N, Gauthier S, Lysy PG. Clinical practice guidelines for severe Alzheimer's disease. Alzheimer's and Dementia 2007;3(4):385-97. - PubMed
Herrmann 2007b
    1. Herrmann N, Gill SS, Bell CM, Anderson GM, Bronskill SE, Shulman K I, et al. A population-based study of cholinesterase inhibitor use for dementia. Journal of the American Geriatrics Society 2007;55(10):1517-23. - PubMed
Herrmann 2008
    1. Herrmann N, Gauthier S. Management of severe Alzheimer disease. Canadian Medical Association Journal 2008;179(12):1279-87. - PMC - PubMed
Herrmann 2011
    1. Herrmann N, Cappell J, Eryavec GM, Lanctôt K. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open label pilot study. CNS Drugs 2011;25(5):425-433. - PubMed
Herrmann 2013
    1. Herrmann N, Lanctôt KL, Hogan DB. Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. Alzheimer's Research &Therapy 2013;5(S1):S5. - PMC - PubMed
Herrmann 2018
    1. Herrmann N. Cholinesterase inhibitor discontinuation: the buck stops here. American Journal of Geriatric Psychiatry 2018;26(2):148-9. - PubMed
Higgins 2011
    1. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hogan 2014
    1. Hogan DB. Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer Disease. Canadian Journal of Psychiatry 2014;59(12):618-23. - PMC - PubMed
Hsiung 2008
    1. Hsiung GY, Feldman HH. Pharmacological treatment in moderate-to-severe Alzheimer's disease. Expert Opinion on Pharmacotherapy 2008;9(15):2575-82. - PubMed
Iverson 2002
    1. Iverson GL, Hopp GA, DeWolfe K, Solomons K. Measuring change in psychiatric symptoms using the Neuropsychiatric Inventory: Nursing Home version. International Journal of Geriatric Psychiatry 2002;17:438-43. - PubMed
Jacques 2000
    1. Jacques A, Jackson G. Understanding dementia. 3rd edition. Edinburgh: Churchill Livingstone, 2000.
Kalra 1996
    1. Kalra S, Bergeron C, Lang A. Lewy body disease and dementia. Archives of Internal Medicine 1996;156:487-93. - PubMed
Kaufer 1998
    1. Kaufer DI, Cummings JL, Christine D, Bray T, Castellon C, Masterman D, et al. Assessing the impact of neuropsychiatric symptoms in Alzheimer's disease: the Neuropsychiatric Inventory caregiver Distress scale. Journal of the American Geriatrics Society 1998;46(2):210-5. - PubMed
Kavanagh 2011
    1. Kavanagh S, Van Baelen B, Schauble B. Long-term effects of galantamine on cognitive function in Alzheimer's disease: a large-scale international retrospective study. Journal of Alzheimer's disease 2011;27(3):521-30. - PubMed
Kertesz 2008
    1. Kertesz A, Morlg D, Light M, Blair M, Davidson W, Jesso S, et al. Galantamine in frontotemporal dementia and primary progressive aphasia. Dementia and Geriatric Cognitive Disorders 2008;25(2):178-85. - PubMed
Kim 2011
    1. Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD. Dementia medications and risk of falls, syncope and related adverse events: meta-analysis of randomized controlled trials. Journal of the American Geriatrics Society 2011;59(6):1019-31. - PMC - PubMed
Knapp 2017
    1. Knapp M, King D, Romeo R, Adams J, Baldwin A, Ballard C, et al. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's Disease (the DOMINO-AD trial). International Journal of Geriatric Psychiatry 2017;32:1205-16. - PMC - PubMed
Lingjaerde 1987
    1. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs, and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatrica Scandinavica 1987;s334:1-100. - PubMed
Livingston 2020
    1. Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet 2020;396:413-46. - PMC - PubMed
Lopez 2009
    1. Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. Journal of Neurology, Neurosurgery & Psychiatry 2009;80:600-7. - PMC - PubMed
Marin 1991
    1. Marin RS, Biedrzycki RC, Firinciogullari S. Reliability and validity of the Apathy Evaluation Scale. Psychiatry Research 1991;38(2):143-62. - PubMed
McKeith 2006
    1. McKeith IG. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy Bodies (DLB): report of the Consortium on DLB International Workshop. Journal of Alzheimer's Disease 2006;9(Suppl 3):417-23. - PubMed
McShane 2019
    1. McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, et al. Memantine for dementia. Cochrane Database of Systematic Reviews 2019, Issue 3. Art. No: CD003154. [DOI: 10.1002/14651858.CD003154.pub6] - DOI - PMC - PubMed
Mohs 1997
    1. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer’s Disease Assessment Scale that broaden its scope.The Alzheimer's Disease Cooperative Study. Alzheimer Disease and Associated Disorders 1997;11(S2):S13–21. - PubMed
Mohs 2001
    1. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 2001;57:489-95. - PubMed
Mok 2004
    1. Mok W, Chow TW, Zheng L, Mack WJ, Miller C. Clinicopathological concordance of dementia diagnoses by community versus tertiary care clinicians. American Journal of Alzheimer's Disease and Other Dementias 2004;19:161-5. - PMC - PubMed
Molloy 1991
    1. Molloy DW, Alemayehu E, Roberts R. Reliability of a Standardized Mini-Mental State Examination compared with the traditional Mini-Mental State Examination. American Journal of Psychiatry 1991;148(1):102-5. - PubMed
Morris 1993
    1. Morris J. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414. - PubMed
Nakamura 2014
    1. Nakamura Y, Kitamura S, Homma A, Shiosakai K, Matsui D. Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan. Expert Opinion in Pharmacotherapy 2014;15(7):913-25. - PMC - PubMed
NICE 2006
    1. National Institute for Health and Clinical Excellence. Dementia: Supporting people with dementia and their carers in health and social care. London (UK): National Institute for Health and Clinical Excellence; 2006. Clinical guideline [CG42].
Nordberg 2009
    1. Nordberg A, Darreh-Shori T, Peskind E, Soininen H, Mousavi M, Lane R. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. Current Alzheimer Research 2009;6:3-13. - PMC - PubMed
O'Brien 2015
    1. O'Brien JT, Thomas A. Vascular dementia. Lancet Neurology 2015;386:1698-706. - PubMed
O'Regan 2015
    1. O'Regan J, Lanctôt KL, Mazareeuw G, Herrmann N. Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials. Journal of Clinical Psychiatry 2015;76(11):e1424-31. - PubMed
Park‐Wyllie 2009
    1. Park-Wyllie LY, Mamdani MM, Li P, Gill SS, Laupacis A, Juurlink DN. Cholinesterase inhibitors and hospitalization for bradycardia: a population-based study. PLoS Medicine 2009;6(9):1-9. - PMC - PubMed
Parnetti 2002
    1. Parnetti L, Amici S, Lanari A, Romani C, Antognelli C, Adreasen N, et al. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurological Sciences 2002;23:S95-6. - PubMed
Parsons 2010
    1. Parsons C, Hughes CM, Passmore AP, Lapane KL. Withholding, discontinuing and withdrawing medications in dementia patients at the end of life: a neglected problem in the disadvantaged dying? Drugs and Aging 2010;27(6):435-49. - PubMed
Parsons 2014
    1. Parsons C, McCorry N, Murphy K, Byrne S, O'Sullivan D, O'Mahony, et al. Assessment of factors that influence physician decision making regarding medication use in patients with dementia at the end of life. International Journal of Geriatric Psychiatry 2014;29(3):281-90. - PubMed
Pirttila 2004
    1. Pirttila T, Wilcock G, Truyen L, Damaraju CV. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial. European Journal of Neurology 2004;11:734-41. - PubMed
Puangthong 2009
    1. Puangthong U, Hsiung GR. Critical appraisal of the long-term impact of memantine in treatment of moderate to severe Alzheimer's disease. Neuropsychiatric Disease and Treatment 2009;5:553-61. - PMC - PubMed
Puri 2011
    1. Puri B, Treasaden I. Textbook of Psychiatry. 3rd edition. London: Churchill Livingstone, 2011.
Qaseem 2008
    1. Qaseem A, Snow V, Cross JT, Forciea MA, Hopkins R, Shekelle P, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Annals of Internal Medicine 2008;148:370-8. - PubMed
Querferth 2010
    1. Querferth H, LaFerla F. Alzheimer's disease: mechanisms of disease. The New England Journal of Medicine 2010;362:329-44. - PubMed
Raina 2008
    1. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Annals of Internal Medicine 2008;148(5):379-97. - PubMed
Rainer 2011
    1. Rainer M, Wuschitz A, Jagsch C, Erb C, Chirikdjian JJ, Mucke HA. Memantine in moderate to severe Alzheimer's disease: an observational post-marketing study. Journal of Neural Transmission 2011;118(8):1255-9. - PubMed
Reeve 2018
    1. Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin P, et al. Evidence-based clinical practice guideline for deprescribing cholinesterase inhibitors and memantine. Sydney (Australia). The University of Sydney, NHMRC Partnership Centre: Dealing with Cognitive and Related Functional Decline in Older People (Cognitive Decline Partnership Centre), Bruyère Research Institute, Deprescribing Guidelines in the Elderly Project; 2018 February.
Reisberg 1988
    1. Reisberg B. Functional assessment staging (FAST). Psychopharmacology Bulletin 1988;24:653-9. - PubMed
Reisberg 2006
    1. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. Archives of Neurology 2006;63(1):49-54. - PubMed
Renn 2018
    1. Renn BN, Asgbar-Ali AA, Thielke S, Catic A, Martini SR, Mitchell BG, Kunik ME. A systematic review of practice guidelines and recommendations for discontinuation of cholinesterase inhibitors in dementia. American Journal of Geriatric Psychiatry 2018;26(2):134-147. - PMC - PubMed
Rodda 2009
    1. Rodda J, Walker Z. Ten years of cholinesterase inhibitors. International Journal of Geriatric Psychiatry 2009;24(5):437-42. - PubMed
Rodda 2012
    1. Rodda J, Carter J. Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. BMJ 2012;344(e2986):1-6. - PubMed
Rogers 2000
    1. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study. European Neuropsychopharmacology 2000;10:195-203. - PubMed
Rolinski 2012
    1. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database of Systematic Reviews 2012, Issue 3. Art. No: CD006504. [DOI: 10.1002/14651858.CD006504.pub2] - DOI - PMC - PubMed
Rosen 1984
    1. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. American Journal of Psychiatry 1984;141:1356-64. - PubMed
Rountree 2009
    1. Rountree SD, Cahn W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimer's Research & Therapy 2009;1(2):7. - PMC - PubMed
Rountree 2013
    1. Rountree SD, Atri A, Lopez OL, Doody RS. Effectiveness of antidementia drugs in delaying Alzheimer's disease progression. Alzheimer's and Dementia 2013;9(3):338-45. - PubMed
Savic 2013
    1. Savic A, Mimica N. Two cases of loss of consciousness after long-term memantine treatment. Journal of the American Medical Directors Association 2013;14:375-376. - PubMed
Saxton 1990
    1. Saxton J, McGonigle-Gibson K, Swihart A, Miller M, Boller F. Assessment of the severely impaired patient: description and validation of a new neuropsychological Test Battery. Psychological Assessment: A Journal of Consulting and Clinical Psychology 1990;2:298-303.
Scheltens 2016
    1. Scheltens P, Blennow K, Breteler MMB, Strooper B, Frisoni BG, Salloway S, et al. Alzheimer's Disease. Lancet 2016;388:505-17. - PubMed
Schmitt 2006
    1. Schmitt FA, Wichems CH. A systematic review of assessment and treatment of moderate to severe Alzheimer's disease. Primary Care Companion to the Journal of Clinical Psychiatry 2006;8(3):158-9. - PMC - PubMed
Schneider 1997
    1. Schneider L, Olin J, Doody R, Clark CM, Morris JC, Reisberg B, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change. Alzheimer Diease and Associated Disorders 1997;11(Suppl 2):22-32. - PubMed
Schulz 2011
    1. Schulz JB, Rainer M, Klünemann HH, Kurz A, Wolf S, Sternberg K, et al. Sustained effects of once-daily memantine treatment on cognition and functional communication skills in patients with moderate to severe Alzheimer's disease: results of a 16-week open-label trial. Journal of Alzheimer's Disease 2011;25(3):463-75. - PubMed
Scott 2015
    1. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Internal Medicine 2015;175(8):827-34. - PubMed
Seltzer 2007
    1. Seltzer B. Is long-term treatment of Alzheimer's disease with cholinesterase inhibitor therapy justified? Drugs & Aging 2007;24(11):881-90. - PubMed
Sinforiani 2012
    1. Sinforiani E, Pasotti C, Chiapella L, Malinverni P, Zucchella C. Memantine in Alzhiemer's disease: experience in an Alzheimer's disease assessment unit. Aging Clinical and Experimental Research 2012;24(2):193-6. - PubMed
Small 2005
    1. Small GW, Kaufer D, Mendiondo MS, Quarg P, Spiegel R. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. International Journal of Clinical Practice 2005;59:473-7. - PubMed
Smith 2005
    1. Smith SC, Lamping DL, Banerjee S, Harwood R, Foley B, Smith P, Cook JC, Murray J, Prince M, Levin E, Mann A, Knapp M. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technology Assessment 2005;9(10):1-93. - PubMed
Suh 2008
    1. Suh G-H, Jung HY, Lee CU, Choi S, the Korean Galantamine Study Group. Economic and clinical benefits of galantamine in the treatment of mild to moderate Alzheimer's disease in a Korean population: a 52-week prospective study. Journal of Korean Medical Science 2008;23:10-7. - PMC - PubMed
Tariot 2000
    1. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfield S, Ding C, the Galantamine USA-10 study group. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269-76. - PubMed
Toledo 2013
    1. Toledo JB, Cairns NJ, Da X, Chen K, Carter D, Fleisher A, et al. Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathologica Communications 2013;1:65. - PMC - PubMed
Tomlinson 1982
    1. Tomlinson B. Plaques, tangles and Alzheimer's disease. Psychological Medicine 1982;12:449-49. - PubMed
Vann Jones 2014
    1. Vann Jones SA, O'Brien JT. The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies. Psychological Medicine 2014;44:673-83. - PubMed
Voisin 2009
    1. Voisin T, Vellas B. Diagnosis and Treatment of Patients with Severe Alzheimer's Disease. Drugs & Aging 2009;26(2):135-44. - PubMed
Wade 1988
    1. Wade DT, Collin C. The Barthel ADL Index: a standard measure of physical disability? International Disability Studies 1988;10(2):64-7. - PubMed
Walker 2015
    1. Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. Lancet Neurology 2015;386:1683-97. - PMC - PubMed
Wattmo 2011
    1. Wattmo C, Wallin A, Londos E, Minthon L. Long-term outcome and prediction models of activities of daily living in Alzheimer disease with cholinesterase inhibitor treatment. Alzheimer Disease and Associated Disorders 2011;25(1):63-72. - PubMed
Weiner 2000
    1. Weiner MF, Martin-Cook K, Svetlik DA, Saine K, Foster B, Fontaine CS. The quality of life in late-stage dementia (QUALID) scale. Journal of the American Medical Directors Association 2000;1(3):114-6. - PubMed
Wilcock 2008
    1. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. Journal of Clinical Psychiatry 2008;69(3):341-8. - PubMed
Winblad 2001
    1. Winblad B, Engedal K, Soinenen H, Verhey F, Waldemar G, Wimo A, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489-95. - PubMed
Winblad 2003
    1. Winblad B, Engedal K, Sioninen H, Waldemar G, Verhey F, Wimo A, et al. Long-term efficacy of donepezil in patients with mild to moderate Alzheimer's Disease: results from a one-year placebo-controlled study and two-year follow-up study. International Psychogeriatrics 2003;15(S2):293-4.
Winblad 2004
    1. Winblad B, Jelic V. Long-term treatment of Alzheimer Disease: efficacy and safety of acetylcholinesterase inhibitors. Alzheimer Disease and Associated Disorders 2004;18(S1):S2-8. - PubMed
Winblad 2006a
    1. Winblad B, Kilander L, Eriksson S, Minthon L, Båtsman S, Wetterholm AL, et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. Lancet 2006;367(9516):1057-65. - PubMed
Winblad 2006b
    1. Winblad B, Wimo A, Engedal K, Soininen H, Verhey F, Waldemar G, et al. 3-Year Study of Donepezil Therapy in Alzheimers Disease: Effects of Early and Continuous Therapy. Dementia and Geriatric Cognitive Disorders 2006;21:353-63. - PubMed
Winblad 2006c
    1. Winblad B. Severe Alzheimer's disease: benefits of donepezil therapy. International Psychogeriatrics 2006;18(S1):25-31.
Winblad 2009
    1. Winblad B. Review: Donepezil in Severe Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias 2009;24(3):185-92. - PMC - PubMed
Winblad 2016
    1. Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society. Lancet Neurology 2016;15:455-532. - PubMed
World Health Organization 2010
    1. World Health Organization. International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10) Version for 2010. Geneva: World Health Organization, Division of Mental Health, 2010.
Wu 2016
    1. Wu YT, Fratiglioni L, Matthews FE, Lobo A, Breteler MM, Skoag I, et al. Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet Neurology 2016;15(1):116-24. - PubMed
Zaccai 2005
    1. Zaccai J, McCracken C, Brayne C. A systematic review of prevalence and incidence studies of dementia with Lewy bodies. Age and Ageing 2005;34:561-6. - PubMed
Zhu 2013
    1. Zhu CW, Livote EE, Scarmeas N, Albert M, Brandt J, Blacker D, et al. Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease. Alzheimer's and Dementia 2013;9:733-40. - PMC - PubMed

Publication types

MeSH terms